Compare AMCR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCR | EXAS |
|---|---|---|
| Founded | 1926 | 1995 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 11.0B |
| IPO Year | N/A | N/A |
| Metric | AMCR | EXAS |
|---|---|---|
| Price | $8.30 | $101.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 20 |
| Target Price | $10.40 | ★ $77.94 |
| AVG Volume (30 Days) | ★ 21.1M | 10.8M |
| Earning Date | 02-03-2026 | 11-03-2025 |
| Dividend Yield | ★ 6.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $17,401,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | $57.16 | $19.40 |
| Revenue Next Year | $1.28 | $13.51 |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | ★ 28.42 | 14.47 |
| 52 Week Low | $7.67 | $38.81 |
| 52 Week High | $10.45 | $101.95 |
| Indicator | AMCR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 89.13 |
| Support Level | $8.18 | $101.30 |
| Resistance Level | $8.39 | $101.95 |
| Average True Range (ATR) | 0.14 | 0.38 |
| MACD | -0.02 | -1.12 |
| Stochastic Oscillator | 39.29 | 72.00 |
Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.